Shaw Sarah, Amico K Rivet
Department of Health Behavior and Health Education, School of Public Health, University of Michigan, Ann Arbor, MI.
J Acquir Immune Defic Syndr. 2016 Aug 1;72(4):387-99. doi: 10.1097/QAI.0000000000000977.
INTRODUCTION: Youth living with HIV are highly under-represented in the evidence base for adherence interventions, despite their diverse and unique needs and barriers. OBJECTIVE: This systematic review aimed to identify antiretroviral therapy (ART) adherence interventions specifically targeting adolescents and young adults (defined as ages 13-24) with the goal of characterizing the evidence base. METHODS: Articles were identified using the PubMed database and cover work published through September 14, 2015. INCLUSION CRITERIA: (1) average age 13 to 24, (2) HIV positive, (3) on or beginning ART, (4) intervention targeted ART adherence in full or in part, (5) reported adherence, viral load, and/or CD4 count outcomes. Strength of evidence was defined as level 1 [randomized controlled trial (RCT) with significance testing on outcomes], 2 (within group studies with statistical testing on outcomes), 3 (RCTs with descriptive results), or 4 (within group studies with descriptive results). RESULTS: Of 151 articles, 10 met inclusion criteria. Published between 2003 and 2014, these studies evaluated diverse intervention approaches. Most were conducted in the US and were small pilots that have yet to be replicated despite promising results. Only 3 studies met criteria for highest level strength of evidence; 2 supported a phone-based counseling approach with adherence monitors and 1 for weekly individual and family counseling. CONCLUSIONS: Despite nearly 20 years passing since the wide-scale availability of ART, and clear recognition that adolescents and youth adults fair worse on the cascade of HIV care, the evidence base remains sparse and underdeveloped. Promising approaches need replication and more rigorous studies are desperately needed.
引言:尽管感染艾滋病毒的青年有多样化且独特的需求与障碍,但在依从性干预措施的证据基础中,他们的代表性严重不足。 目的:本系统评价旨在确定专门针对青少年和青年(定义为13至24岁)的抗逆转录病毒疗法(ART)依从性干预措施,以对证据基础进行特征描述。 方法:通过PubMed数据库检索文章,涵盖截至2015年9月14日发表的研究。 纳入标准:(1)平均年龄13至24岁;(2)艾滋病毒呈阳性;(3)正在接受或即将开始抗逆转录病毒治疗;(4)干预措施全部或部分针对抗逆转录病毒疗法的依从性;(5)报告了依从性、病毒载量和/或CD4细胞计数结果。证据强度定义为1级[对结果进行显著性检验的随机对照试验(RCT)]、2级(对结果进行统计检验的组内研究)、3级(有描述性结果的随机对照试验)或4级(有描述性结果的组内研究)。 结果:在151篇文章中,10篇符合纳入标准。这些研究发表于2003年至2014年之间,评估了多种不同的干预方法。大多数研究在美国进行,且规模较小,均为试点研究,尽管结果令人鼓舞,但尚未得到重复验证。只有3项研究符合最高证据强度标准;2项研究支持采用配备依从性监测器的电话咨询方法,1项支持每周进行个体及家庭咨询。 结论:尽管抗逆转录病毒疗法广泛应用已近20年,且人们清楚认识到青少年在艾滋病毒治疗连续过程中的情况更糟,但证据基础仍然薄弱且发展不足。有前景的方法需要重复验证,迫切需要开展更严格的研究。
J Acquir Immune Defic Syndr. 2016-8-1
Cochrane Database Syst Rev. 2011-12-7
Cochrane Database Syst Rev. 2012-3-14
Cochrane Database Syst Rev. 2010-3-17
Cochrane Database Syst Rev. 2006-7-19
Cochrane Database Syst Rev. 2010-11-10
Cochrane Database Syst Rev. 2012-7-11
Cochrane Database Syst Rev. 2017-5-18
Glob Health Sci Pract. 2024-4-29
AIDS Patient Care STDS. 2014-3
J Assoc Nurses AIDS Care. 2014
J Int Assoc Provid AIDS Care. 2013